ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced ICONIK Labs, the latest service to leverage its ICONIK technology platform.

ICONIK Labs is an interactive analytics tool that allows Clinical and Medical team members to visualise, analyse and report on large volumes of laboratory data in real time. Using ICONIK Labs’ advanced visualisation capabilities, project teams can interact with data and view trends at any level of detail, including patient, site, study or across an entire program through a series of dynamic filters. ICONIK Labs enhances a study’s quality by instantly identifying sites with an unusual number of lab values outside the normal range and can also improve patient safety by providing Hy’s Law analysis which assists with the detection of subjects at risk of Drug Induced Liver Injury (DILI).

Commenting on the new service, Dr. Steve Cutler, Group President, ICON Clinical Research Services, said: “ICONIK Labs has transformed how study teams review and analyse laboratory data and has enabled a fresh approach to combining lab parameters to review study trends. It enables study teams to quickly uncover actionable insights that support earlier, more informed decision-making and more efficient trial management.”

ICONIK Labs is the latest service to leverage the ICONIK technology platform and follows ICON’s recent announcement of 

. ICONIK Monitoring is a new service that improves quality and reduces the costs of clinical development through more effective use of monitoring resources. ICONIK Patient Safety enables real-time analysis of aggregated patient safety data, giving study teams the ability to uncover potential medical issues in real-time.


News

ICONIK Labs allows visualisation, analysis and reporting on laboratory data in real time